Cingulate Inc. (CING) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 8.52M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 1.93M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -24.92M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $8.52M | (m) | $1.93M | $-24.92M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $9.74M | (m) | $1.76M | $-24.16M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $9.77M | (m) | $1.52M | $-19.94M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $12.10M | (m) | $1.20M | $-20.56M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $10.68M | (m) | $999.17K | $-17.85M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $9.86M | (m) | $1.19M | $-16.40M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $9.45M | (m) | $995.48K | $-15.64M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $10.10M | (m) | $1.09M | $-16.23M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $12.60M | (m) | $932.16K | $-18.70M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $15.17M | (m) | $772.77K | $-21.86M | $633.75K | (m) | (m) | -34.49× | Reported |
| 2023-12-31 | $15.49M | (m) | $812.67K | $-22.76M | $790.00K | (m) | (m) | -28.81× | Reported |
| 2023-09-30 | $12.44M | (m) | $864.54K | $-20.44M | $865.00K | (m) | (m) | -23.63× | Reported |
| 2023-06-30 | $10.64M | (m) | $833.95K | $-18.66M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $8.36M | (m) | $823.76K | $-16.34M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $9.00M | (m) | $800.80K | $-17.50M | $292.34K | (m) | (m) | -59.87× | Reported |
| 2022-09-30 | $8.33M | (m) | (m) | $-15.67M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $11.99M | (m) | (m) | $-26.98M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $10.61M | (m) | (m) | $-24.36M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $8.41M | (m) | $43.84K | $-20.68M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $5.09M | (m) | (m) | $-7.08M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |